SCHEMES - VALUE OVERVIEW
AirPhysio for Medical Schemes - Value Overview
For scheme clinical, funding and managed-care teams.
The Opportunity
Respiratory conditions drive admissions and claims. A low-cost, drug-free adjunct that supports airway clearance and adherence may reduce exacerbations for chronic respiratory members.
What Makes It Fundable
- Low unit cost (R945 incl. VAT).
- Drug-free, no interactions.
- Measurable outcomes via LungSync (adherence, spirometry trend).
- Evidence base in COPD.
Evidence
A real-world matched cohort of 810 COPD patients showed lower 30-day exacerbation and hospitalisation rates with an OPEP device versus standard care (Burudpakdee, 2017).
A systematic review and meta-analysis reported improved sputum clearance and symptom or quality-of-life outcomes with OPEP in COPD (2020).
Proposed Approach
Fund a monitored pilot cohort and review adherence and outcome data before any scaling.
[REVIEW NEEDED BY: scheme clinical-risk lead - clinical and funding assessment]
Next step Let us design a funded, monitored pilot cohort with clear outcome reporting. Health Brands SA - tshepo@therapyonthego.co.za.
Get AirPhysio® — R945 incl. 15% VAT
Drug-free airway clearance. Fulfilled by the official SA store.
This platform records measurements taken by your health practitioner and readings you self-report. It does not diagnose or treat any condition. AirPhysio® is a trademark of its manufacturer; claims are limited to airway clearance and lung-expansion support. Items requiring specialist confirmation are marked for review before external use.